top of page
  • Writer's pictureARQon

Drugs - February 2018

  • International - WHO Drug Information, Volume 31, No. 4

  • International - EDQM Press Release: The Ph. Eur. Revised its General Chapters on Plasticised PVC Materials

  • Australia - European Union Guidelines Adopted in Australia

  • Australia - Guideline: Australian Health Ministers’ Advisory Council: Scheduling Policy Framework for Medicines and Chemicals, Version 1.0

  • China - CFDA Announcement No. 2018/10: Adoption of International Conference on Harmonization (ICH) Guidelines on Technical Requirements for Registration of Pharmaceuticals for Human Use

  • China - CFDA Announcement No. 2018/16: Issuance of Technical Guidance for Phase I Clinical Trial Application of New Drug

  • India - CDSCO Letter No. X-11026/143/16-BD: Issuance of No Objection Certificate for Issuance of Form 29 License to Manufacture Drugs for Purposes of Examination, Test of Analysis for Biological Products (Vaccines & r-DNA Products)

  • Indonesia - Assembly and Submission of Applications: Electronic Submissions

  • Japan - Notification: PSEHB/PED No. 0118/1: ICH Guideline Topic E18 Step 4: Genomic Sampling and Management of Genomic Data

  • Japan - Notice: PSEHB/PED: Q&A on Implementation of Conditional Marketing Authorisation of Medicinal Products

  • Philippines - Marketing Authorization Procedures: Renewal

  • South Korea - Presidential Decree No. 28589: Enforcement Decree of Narcotic Drug Control Act

  • Taiwan - MOWH Announcement No. 1061411970: Amendment to Drug Items Applicable to the Law: The Rare Disease and Orphan Drug Act

  • Thailand - FDA Notification: Drug List exempted from Government Fees

  • Canada - Notice: Adoption of International Council for Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance Document: M7

  • Canada - Register of Innovative Drugs

  • European Union - EMA Press Release: EMA Surveys Pharma Companies on their Preparedness for Brexit

  • European Union - EMA Press Release: Human medicines: Highlights of 2017

  • United Kingdom - Marketing Authorization Procedures: Procedure for Unapproved Drug Use / Compassionate Use

  • United Kingdom - Authorities / Organizations: The Medicines and Healthcare products Regulatory Agency (MHRA) and The National Institute for health and Clinical Excellence (NICE)

  • Brazil - Resolution RDC 250: About the Renewal of Medicinal Product Registration, 20-Oct-2004 (Official Consolidated Version up to Amendments Brought by Resolution RDC 212 of 22-Jan-2018)

  • Gulf Cooperation Council - Circular No. 23-01-2018/0286: Acceptance of Bioequivalence Centers Owned by the Manufacturer,

  • Israel - Quality Assurance: Good Manufacturing Practice and Inspections

  • Saudi Arabia - Communication: Medical Equipment and Medicines Submitted to Value Added Tax at Zero Rate

  • USA - Guidance Bulletin: Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases

  • USA - Guidance Bulletin: Labeling for Combined Hormonal Contraceptives

Contact us at info@arqon.com.


37 views0 comments

Recent Posts

See All

Europe - May 2020

Denmark: New rules mean non-serious adverse events may also need to be reported EU: Application of Regulation (EU) 2017/745 postponed by one year EU: Continued use of lead as a thermal stabiliser in P

EU: MDR delayed to 26 May 2021

Application of the Medical Devices Regulation (MDR) has been deferred by one year, until 26 May 2021, for fear of shortage or delay in getting essential medical devices needed to combat Covid-19. The

EU 2020 MDR Guidance Notes For Class I Manufacturers

There will be no transition period for Class I medical devices which remain in Class I under MDR. From 26th May 2020 onwards, the conformity for Class I medical devices which are not subject to up-cla

bottom of page